Amicus Corp (FOLD) Cash per Single Share

Corporate emblem and logo of Amicus Corp (FOLD)

The scientific potential of Amicus Therapeutics (FOLD) is based on cutting-edge developments in gene therapy and protein chaperones. This is supported by a broad portfolio of drugs for rare pathologies successfully marketed in Europe and the US. Leadership in the enzyme replacement therapy niche provides the company with a global advantage. The cash per share on this chart confirms liquidity, and 0.93 expresses the value of the metric today.

Amicus Pharma (FOLD): Cash Funds per Share from 07/04/2022 to 05/09/2026

Comprehensive metric breakdowns and analytics for Amicus Therapeutics Inc (FOLD)

- market value and analyst target forecast:
- cash position and cash flow details:
General company analysis:FOLD, Amicus Corp
Manufactured product of Amicus Therapeutics, Inc.

Selecting high-quality issuers requires a liquidity analysis via the ratio of net cash to the number of shares, which determines the business's margin of safety in the event of a revenue decline. For Amicus Therapeutics (FOLD), which has transitioned to drug commercialization without M&A activity, the trend of the cash cushion per share reflects the burn rate of reserves for the sales launch, allowing for an assessment of the company's autonomy without external borrowing.